Ralliant (NYSE:RAL) Lowered to Hold Rating by Wall Street Zen

Key Points

• Ralliant (NYSE:RAL) was downgraded to Hold by Wall Street Zen, adding to a mixed analyst picture that still leaves the stock with an overall Moderate Buy rating and an average price target of $73.
• Recent analyst moves have been mixed, with some firms cutting ratings while others raised price targets; current sentiment includes 1 Strong Buy, 7 Buy, 3 Hold, and 1 Sell ratings.
• Ralliant reported Q1 earnings of $0.57 per share, beating estimates, with revenue up 11% year over year, and it guided FY2026 EPS to $2.53-$2.69.

Ralliant (NYSE:RAL - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Sunday.

Several other equities research analysts have also recently commented on RAL. Vertical Research cut Ralliant from a "buy" rating to a "hold" rating and set a $65.00 price target for the company. in a research note on Wednesday, May 27th. Morgan Stanley raised their price objective on shares of Ralliant from $68.00 to $85.00 and gave the company an "overweight" rating in a research report on Tuesday, June 23rd. Royal Bank Of Canada lifted their target price on shares of Ralliant from $64.00 to $71.00 and gave the company a "sector perform" rating in a research note on Thursday, July 16th. Truist Financial reissued a "buy" rating and issued a $68.00 target price (up from $53.00) on shares of Ralliant in a research report on Wednesday, May 13th. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Ralliant in a research report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $73.00.

Ralliant Price Performance

Shares of NYSE:RAL opened at $69.55 on Friday. The company's fifty day moving average is $66.43 and its two-hundred day moving average is $53.80. The company has a market cap of $7.78 billion and a P/E ratio of -6.36. Ralliant has a 12-month low of $37.27 and a 12-month high of $75.41. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73.

Ralliant (NYSE:RAL - Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business had revenue of $534.60 million during the quarter. The firm's revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities analysts expect that Ralliant will post 2.64 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ralliant

A number of large investors have recently added to or reduced their stakes in the stock. Danske Bank A S bought a new position in shares of Ralliant in the fourth quarter valued at approximately $25,000. V Square Quantitative Management LLC bought a new stake in shares of Ralliant during the 4th quarter worth $26,000. Allworth Financial LP boosted its holdings in shares of Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company's stock worth $26,000 after buying an additional 293 shares during the period. Palisade Asset Management LLC acquired a new position in Ralliant in the 3rd quarter valued at $26,000. Finally, BOKF NA acquired a new position in Ralliant in the 3rd quarter valued at $29,000.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.